ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Bryan Paul SchneiderFengmin ZhaoTarah Jean BallingerSofia F GarciaFei ShenShamsuddin ViraniDavid CellaCasey L BalesGuanglong JiangLisa HayesNadia MillerJayanthi SrinivasiahErica M Stringer-ReasorAmi ChitaliaAndrew A DavisDella F MakowerJason IncorvatiMelissa A SimonEdith P MitchellAngela M DeMicheleKathy D MillerJoseph A SparanoLynne I WagnerAntonio C WolffPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Germline variation did not predict risk of TIPN in Black women receiving (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel. Once weekly paclitaxel was associated with significantly more grade 2-4 TIPN and required more dose reductions than once every 3 weeks docetaxel.
Keyphrases
- early stage
- dna repair
- gestational age
- locally advanced
- high glucose
- polycystic ovary syndrome
- diabetic rats
- sentinel lymph node
- study protocol
- breast cancer risk
- clinical trial
- phase iii
- phase ii
- dna damage
- pregnancy outcomes
- chemotherapy induced
- radiation therapy
- randomized controlled trial
- endothelial cells
- metastatic breast cancer
- metabolic syndrome
- adipose tissue
- cervical cancer screening
- lymph node
- insulin resistance
- placebo controlled